PRDX5

Across TCGA pan-cancer cohorts, PRDX5 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRDX5 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PRDX5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRDX5 expression acts as an unfavorable survival marker.

LUAD and KIRC are the cancer types where PRDX5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.098	0.791	<.001	18	view →
KIRC	OS	Median	All	0.249	0.805	.010	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PRDX5–LUAD (DFS)

Open the LUAD breakdown →